PTH prodrugs

Abstract The present invention relates to a PTH prodrug or a pharmaceutically acceptable salt thereof comprising a conjugate D-L, wherein D is a PTH moiety; -L comprises a reversible prodrug linker moiety -L-, which moiety -L 1- is connected to the PTH moiety -D through a functional group of PTH; wh...

Full description

Saved in:
Bibliographic Details
Main Authors Sprogøe, Kennett, Zettler, Joachim, Krusch, Mathias, Maitro, Guillaume, Wegge, Thomas, Cleemann, Felix
Format Patent
LanguageEnglish
Published 28.09.2023
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Abstract The present invention relates to a PTH prodrug or a pharmaceutically acceptable salt thereof comprising a conjugate D-L, wherein D is a PTH moiety; -L comprises a reversible prodrug linker moiety -L-, which moiety -L 1- is connected to the PTH moiety -D through a functional group of PTH; wherein -L 1- is substituted with L2 -Z' and is optionally further substituted; wherein -L 2 -is a single chemical bond or a spacer moiety; and -Z' is a water-insoluble carrier moiety. The PTH prodrug may be used to treat, control, delay or prevent diseases which can be treated with PTH including hypoparathyroidism (HP). The PTH prodrug may be administered via subcutaneous injection.
Bibliography:Application Number: AU20220256158